Related Experiment Video
Updated: Jul 11, 2026
09:37
Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
Published on: August 15, 2014
Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor.
Taichi Yamamoto1, Hyung Won Choi, Robert O Ryan
1Center for Prevention of Obesity, Diabetes, and Cardiovascular Disease, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Analytical Biochemistry
|October 10, 2007
Summary
Apolipoprotein E (apoE) binding to the low-density lipoprotein receptor (LDLR) was studied. Lipid-associated apoE showed isoform-specific binding, offering insights into cholesterol homeostasis.
Area of Science:
- Biochemistry
- Molecular Biology
- Lipid Metabolism
Background:
- Apolipoprotein E (apoE) is crucial for plasma cholesterol homeostasis.
- It acts as a ligand for the low-density lipoprotein receptor (LDLR) family.
- Understanding apoE-LDLR interactions is key to managing cholesterol levels.
Purpose of the Study:
- To investigate the binding characteristics of Apolipoprotein E (apoE) isoforms to the soluble low-density lipoprotein receptor (sLDLR).
- To explore the influence of lipid association and specific domains of apoE on receptor binding.
- To establish a method for studying molecular interactions affecting cholesterol homeostasis.
Main Methods:
- Utilized a fluorescence-based assay for studying receptor-ligand interactions.
- Performed competition experiments to assess binding affinities.
- Conducted kinetic studies to analyze time-dependent binding effects.
Main Results:
- Demonstrated isoform-specific binding differences for lipid-associated apoE N-terminal (NT) domains to sLDLR.
- Showed that lipid-associated, but not lipid-free, full-length apoE3 binds to sLDLR.
- Revealed that receptor-associated protein inhibits apoE3-NT-phospholipid complex binding to sLDLR.
- Observed time-dependent effects in the interaction of apoE3-NT-phospholipid complex with sLDLR.
Conclusions:
- The study provides a discerning method for investigating molecular interactions between apoE and LDLR.
- Findings highlight the importance of lipid association and apoE isoforms in receptor binding.
- These insights are critical for understanding and potentially modulating whole-body cholesterol homeostasis.
Related Concept Videos
01:38Receptor-mediated Endocytosis
Overview
01:45Regulation of Nuclear Protein Sorting
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
01:30Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
01:32Lipids as Anchors
In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains the...
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains the...